40 73

Cited 0 times in

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이혜원-
dc.contributor.author한대훈-
dc.contributor.author이재승-
dc.date.accessioned2020-12-11T07:59:57Z-
dc.date.available2020-12-11T07:59:57Z-
dc.date.issued2020-11-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180739-
dc.description.abstractBy pegylated interferon (PegIFN)-free direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection, a sustained virological response (SVR) rate >95% can be attained with a satisfactory tolerability and shorter treatment duration. However, it remains controversial whether there is any difference in prognosis depending on regimens-PegIFN or DAAs. We compared the probabilities of hepatocellular carcinoma (HCC) development between patients achieving an SVR by PegIFN/ribavirin (PegIFN group, n = 603) and DAAs (DAAs group, n = 479). The DAAs group was significantly older and had a higher proportion of cirrhosis than the PegIFN group. Before adjustment, the DAAs group had a higher HCC incidence than the PegIFN group (p < 0.001). However, by multivariate analyses, the DAAs (vs. PegIFN) group was not associated with HCC risk (adjusted hazard ratio 0.968, 95% confidence interval 0.380-2.468; p = 0.946). Old age, male, higher body mass index, cirrhosis, and lower platelet count were associated with increased HCC risk (all p < 0.05). After propensity score matching (PSM), a similar HCC risk between the two groups was observed (p = 0.372). We also compared HCC incidences according to sofosbuvir (SOF)-based and SOF-free DAAs, showing a similar risk in both groups before adjustment (p = 0.478) and after PSM (p = 0.855). In conclusion, post-SVR HCC risks were comparable according to treatment regimens; PegIFN- vs. DAA-based regimens and SOF-based vs. SOF-free DAA regimens. Further studies with a longer follow-up period are required.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherMDPI-
dc.relation.isPartOfCANCERS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleHepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorDai Hoon Han-
dc.contributor.googleauthorHye Jung Shin-
dc.contributor.googleauthorJae Seung Lee-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorBeom Kyung Kim-
dc.identifier.doi10.3390/cancers12113414-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA02226-
dc.contributor.localIdA03318-
dc.contributor.localIdA03318-
dc.contributor.localIdA04273-
dc.contributor.localIdA04273-
dc.relation.journalcodeJ03449-
dc.identifier.eissn2072-6694-
dc.identifier.pmid33217965-
dc.subject.keywordcomparison-
dc.subject.keyworddirect-acting antivirals-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordinterferon-
dc.subject.keywordprognosis-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor한대훈-
dc.contributor.affiliatedAuthor한대훈-
dc.citation.volume12-
dc.citation.number11-
dc.citation.startPage3414-
dc.identifier.bibliographicCitationCANCERS, Vol.12(11) : 3414, 2020-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.